Key clinical point: Upadacitinib led to early and sustained clinically meaningful improvements in patient-reported outcomes (PRO) in patients with psoriatic arthritis (PsA) having an inadequate response to nonbiologic disease-modifying antirheumatic drugs (non-bDMARD).
Major finding: A greater proportion of patients treated with 15 and 30 mg upadacitinib vs. placebo showed clinically meaningful improvement in the patient global assessment of disease activity, pain, and health assessment questionnaire disability index as early as week 2 ( P < .01) which was maintained or further improved at weeks 12 and 24 ( P < .01).
Study details: This was a post hoc analysis of the phase 3 SELECT-PsA 1 trial, including 1,704 patients with PsA who had an inadequate response to at least 1 non-bDMARD and who were randomly assigned to upadacitinib, adalimumab, or placebo.
Disclosures: This work was funded by AbbVie. K Kato, E McDearmon-Blondell, P Zueger, and CD Saffore reported being employees and stockholders of AbbVie. The other authors reported ties with several sources including AbbVie.
Source: Strand V et al. Rheumatol Ther. 2021;8:1789-1808 (Oct 12). Doi: 10.1007/s40744-021-00379-9.